Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | SPHK2 | Q9NRA0 | 1/20 | 0.31 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL406617 | 1.00 | CYP3A4 (0.32) | CYP3A4HSD17B10SPHK2SPHK1 | |
| SCHEMBL22790824 | 1.00 | CYP3A4 (0.32) | CYP3A4HSD17B10SPHK2SPHK1 | |
| SCHEMBL406109 | 1.00 | CYP3A4 (0.32) | CYP3A4HSD17B10SPHK2SPHK1 | |
| SCHEMBL20825495 | 1.00 | CYP3A4 (0.32) | CYP3A4HSD17B10SPHK2SPHK1 | |
| SCHEMBL3244476 | 0.95 | — | — | |
| SCHEMBL17914307 | 0.86 | HSD17B10 (0.39) | HSD17B10SPHK2SPHK1 | |
| SCHEMBL4373347 | 0.86 | HSD17B10 (0.39) | HSD17B10SPHK2SPHK1 | |
| SCHEMBL17914309 | 0.86 | HSD17B10 (0.39) | HSD17B10SPHK2SPHK1 | |
| SCHEMBL725089 | 0.86 | HSD17B10 (0.39) | HSD17B10SPHK2SPHK1 | |
| SCHEMBL8651797 | 0.86 | HSD17B10 (0.39) | HSD17B10SPHK2SPHK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230355622-A1 | METHODS OF CHEMOVACCINATION AGAINST PLASMODIUM INFECTIONS | MERCK SHARP & DOHME LLC (US) | 2023-11-09 | — | — | US | disclosed |
| US-20220331321-A1 | ANTIMALARIAL AGENTS | MERCK SHARP & DOHME CORP. (US) | 2022-10-20 | — | — | US | disclosed |
| US-20140243322-A1 | BIVALENT BROMODOMAIN LIGANDS, AND METHODS OF USING SAME | COFERON, INC. (US) | 2014-08-28 | — | — | US | disclosed |
| WO-2013033270-A2 | BROMODOMAIN LIGANDS CAPABLE OF DIMERIZING IN AN AQUEOUS SOLUTION, AND METHODS OF USING SAME | COFERON, INC. (US) | 2013-03-07 | — | — | WO | disclosed |
| WO-2013033269-A1 | BIOORTHOGONAL MONOMERS CAPABLE OF DIMERIZING AND TARGETING BROMODOMAINS AND METHODS OF USING SAME | COFERON, INC. (US) | 2013-03-07 | — | — | WO | disclosed |
| CN-1118496-C | Preparation of conjugated diene and/or monovinyl arene polymer | SHENGJIE INDUSTRY CO LTD JIANG (CN) | 2003-08-20 | — | — | CN | disclosed |
| CN-1269371-A | Preparation of conjugated diene and/or monovinyl arene polymer | JIANGSU SHENGJIE INDUSTRY CO L (CN) | 2000-10-11 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140243322-A1 | BIVALENT BROMODOMAIN LIGANDS, AND METHODS OF USING SAME | BRDT, BRD2, BRD4 | CYP3A4 4749/4885HSD17B10 3054/4885SPHK2 2332/4885 |
| US-20230355622-A1 | METHODS OF CHEMOVACCINATION AGAINST PLASMODIUM INFECTIONS | CTSL, PRCP, CPB1 | CYP3A4 2484/4885HSD17B10 1706/4885SPHK2 1296/4885 |
| US-20220331321-A1 | ANTIMALARIAL AGENTS | CTSL, SERPINA3, SERPINB1 | CYP3A4 971/4885HSD17B10 1374/4885SPHK2 1727/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.